EVH Evolent Health
- 23.360
- -0.100-0.43%
- 24.160
- +0.800+3.42%
Evolent Health News
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
Evolent Health Is Maintained at Buy by Citigroup
Evolent Health Analyst Ratings
Citi Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $33
TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Reaffirms Their Buy Rating on Evolent Health (EVH)
Evolent Health Analyst Ratings
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Sticks to Their Buy Rating for Evolent Health (EVH)
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $45
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Announces Target Price $33
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $43
Evolent Health Buy Rating Affirmed With Increased Price Target Amid Growth Prospects and M&A Speculation
Evolent Health Is Maintained at Buy by Truist Securities
Analysis
Price Target
No Data
No Data